Dephosphorylation of the EGFR protein by calcineurin at serine 1046/1047 enhances its stability.

Takahiro Masaki, Makoto Habara, Shusaku Shibutani, Shunsuke Hanaki, Yuki Sato, Haruki Tomiyasu, Midori Shimada

Biochemical and biophysical research communications 2023 Jan 22

filter terms:

The epidermal growth factor receptor (EGFR) is highly expressed or abnormally activated in several types of cancers, such as lung and colorectal cancers. Inhibitors that suppress the tyrosine kinase activity of EGFR have been used in the treatment of lung cancer. However, resistance to these inhibitors has become an issue in cancer treatment, and the development of new therapies that inhibit EGFR is desired. We found that calcineurin, a Ca2+/calmodulin-activated serine/threonine phosphatase, is a novel regulator of EGFR. Inhibition of calcineurin by FK506 treatment or calcineurin depletion promoted EGFR degradation in cancer cells. In addition, we found that calcineurin dephosphorylates EGFR at serine (S)1046/1047, which in turn stabilizes EGFR. Furthermore, in human colon cancer cells transplanted into mice, the inhibition of calcineurin by FK506 decreased EGFR expression. These results indicate that calcineurin stabilizes EGFR by dephosphorylating S1046/1047 and promotes tumor growth. These findings suggest that calcineurin may be a new therapeutic target for cancers with high EGFR expression or activation. Copyright © 2022 Elsevier Inc. All rights reserved.

Citation

Takahiro Masaki, Makoto Habara, Shusaku Shibutani, Shunsuke Hanaki, Yuki Sato, Haruki Tomiyasu, Midori Shimada. Dephosphorylation of the EGFR protein by calcineurin at serine 1046/1047 enhances its stability. Biochemical and biophysical research communications. 2023 Jan 22;641:84-92